These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 26857707)

  • 1. Expanding roles of the hypoxia-response network in chronic kidney disease.
    Tanaka T
    Clin Exp Nephrol; 2016 Dec; 20(6):835-844. PubMed ID: 26857707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors].
    Nangaku M
    Rinsho Ketsueki; 2021; 62(8):938-943. PubMed ID: 34497234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
    Uchida L; Tanaka T; Saito H; Sugahara M; Wakashima T; Fukui K; Nangaku M
    Am J Physiol Renal Physiol; 2020 Feb; 318(2):F388-F401. PubMed ID: 31841388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
    Kaplan JM; Sharma N; Dikdan S
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia, HIF, and Associated Signaling Networks in Chronic Kidney Disease.
    Liu J; Wei Q; Guo C; Dong G; Liu Y; Tang C; Dong Z
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
    Sakashita M; Tanaka T; Nangaku M
    Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration.
    Yu X; Fang Y; Liu H; Zhu J; Zou J; Xu X; Jiang S; Ding X
    Nephrol Dial Transplant; 2012 Aug; 27(8):3110-9. PubMed ID: 22399494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-Inducible Factor and Oxygen Biology in the Kidney.
    Sugahara M; Tanaka T; Nangaku M
    Kidney360; 2020 Sep; 1(9):1021-1031. PubMed ID: 35369554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
    Maruno S; Tanaka T; Nangaku M
    Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mechanistic link between renal ischemia and fibrosis.
    Tanaka T
    Med Mol Morphol; 2017 Mar; 50(1):1-8. PubMed ID: 27438710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multiple consequences of HIF activation in CKD].
    Tanaka T
    Nihon Yakurigaku Zasshi; 2020; 155(1):30-34. PubMed ID: 31902844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
    Hasegawa S; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):331-338. PubMed ID: 30067604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of hypoxia, increased oxygen consumption, and hypoxia-inducible factor-1 alpha in progression of chronic kidney disease.
    Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2010 Jan; 19(1):43-50. PubMed ID: 19779337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-Inducible Factors and Diabetic Kidney Disease-How Deep Can We Go?
    Stanigut AM; Pana C; Enciu M; Deacu M; Cimpineanu B; Tuta LA
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIF Activation Against CVD in CKD: Novel Treatment Opportunities.
    Tanaka T; Eckardt KU
    Semin Nephrol; 2018 May; 38(3):267-276. PubMed ID: 29753402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure.
    Nangaku M
    J Am Soc Nephrol; 2006 Jan; 17(1):17-25. PubMed ID: 16291837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
    Kular D; Macdougall IC
    Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.